Various guidelines have been established for the use of TNFi in AS-associated AU [11,12,13]; the American Academy of Ophthalmology (AAO) recommends TNF inhibitors as second-line immunomodulatory agents for severe uveitis associated with spondyloarthritis. Here, TNF is linked to uveitis.